Trial Profile
A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Verdiperstat (Primary)
- Indications Multiple system atrophy
- Focus Therapeutic Use
- 30 Jul 2022 Status changed from recruiting to completed.
- 08 Jun 2011 New trial record